Lipid peroxidation reactions during reperfusion after cardiac arrest may contribute to postischemic cerebral hypoperfusion, which in turn can contribute to permanent neurological dysfunction. We designed this study to determine whether the aminosteroid U74006F, a putative inhibitor of lipid peroxidation, mitigates cerebral multifocal hypoperfusion after cardiac arrest. 
W e hypothesize that after cardiac arrest and reperfusion, the cerebral postresuscitation syndrome 1 consists of four components 2 : 1) perfusion failure, 2) reoxygenation cascades leading to lipid peroxidation, 3) self-intoxication from postischemic extracerebral organs, and 4) blood dyscrasias from stasis. This study concerns a drug that might affect all four components. U74006F {21-[4-(2,6-di-l-pyrrolidinyl-4-pyrimidinyl)-l-piperazinyl]-16a-methyl-pregna-l,4,9(ll)-triene-3,20-dione; monomethane sulfonate}, 3 a new putative inhibitor of lipid peroxidation, is a steroid that mimics the pharmacological actions of high-dose methylprednisolone while remaining devoid of classical glucocorticoid actions. 4 U74006F inhibited irondependent lipid peroxidation in vitro, 3 protected (with pretreatment) against postischemic histological brain damage in gerbils, 5 reduced infarct size in cats with temporary middle cerebral artery occlusion, 6 attenuated cerebral hypoperfusion after global brain ischemia in cats, 7 and gave positive results in experimental central nervous system trauma, 8 vasogenic cerebral edema, 9 and hemorrhagic shock. 10 It seemed to enhance survival after cardiac arrest and openchest cardiopulmonary resuscitation (CPR) in dogs. 11 We evaluated the effects of U74006F on the postcardiac arrest cerebral hyperemia-hypoperfusion sequence 12 as global, regional, and local (multifocal) cerebral blood flow (CBF) measured by the stable xenon-enhanced computed tomography (Xe-CT) method. study followed previous studies with the Xe-CT method of postarrest CBF after external CPR, 16 open-chest CPR, 17 or cardiopulmonary bypass (as in this study) 17 and with postarrest hypertension and hemodilution. 18 
Materials and Methods
This project was approved by the Animal Use Committee of the University of Pittsburgh. We used 22 healthy, custom-bred male coon hounds from the same breeding colony, mean age 10 (range 8-12) months and mean weight 19 (range 18-24) kg.
First, we conducted pilot studies in two dogs without cardiac arrest to rule out side effects of U74006F. Therapeutic intravenous doses in the above-mentioned studies seem to be 1-3 mg/kg. One normal, unanesthetized, unmonitored, spontaneously breathing dog received 1 mg/kg/min i.v. U74006F for 30 minutes (total dose 30 mg/kg). This infusion of an overdose resulted in no abnormal behavior, no overall functional changes, and no other side effects. Another normal dog was anesthetized with 50%:50% nitrous oxide:oxygen (N 2 O:O 2 ) plus 0.5% halothane and paralyzed with pancuronium in a steady state with intermittent positive-pressure ventilation and invasive monitoring without cardiac arrest. Again, 1 mg/kg/min i.v. U74O06F was administered for 30 minutes (total dose 30 mg/kg). This infusion resulted in no change from baseline of mean arterial blood pressure (MABP) or other monitored cardiovascular, pulmonary, or metabolic variables (see subsequent protocol), except that cardiac output increased from 4.5 1 before to 7.6 1 at 2 hours after U74006F infusion.
We then conducted the CBF study in 10 dogs, using our established model of ventricular fibrillation cardiac arrest (no blood flow) of 12.5 minutes with reperfusion by cardiopulmonary bypass for s 5 minutes postarrest and intermittent positive-pressure ventilation to 4 hours. 1719 ' 20 The five control dogs (group I) also served other studies 1718 and therefore
were not placebo controlled. The five U74006F-treated dogs (group II) were, however, treated by the same team concurrent with the control dogs. Anesthesia was induced with ketamine and maintained with 50%: 50% N 2 O:O 2 plus halothane by endotracheal intermittent positive-pressure ventilation. We continuously monitored the electrocardiogram, heart rate, MABP, central venous pressure, end-tidal CO2, and central venous (core) temperature (T CT ). We intermittently monitored arterial blood gases and hematocrit (Hct). We controlled MABP at 100±10 mm Hg (mean±SD) by adjusting the halothane concentration before and by using norepinephrine or trimethaphan after cardiac arrest, central venous pressure at 5-15 mm Hg, T m at 37.5±0.5°C, PaOj at £100 mm Hg, PacOj at 30-35 mm Hg, base excess at ±7 meq/1, and blood glucose concentration at 100-175 mg/dl before arrest. In preparation for the insult and during paralysis with pancuronium and intermittent positive-pressure ventilation, inhalation anesthesia was reduced with 100% O 2 for 1 minute, followed by room air for 4 minutes. Ventricular fibrillation was induced by external transthoracic electric shock. At the end of ventricular fibrillation of 12.5 minutes, resuscitation was begun with Q.0125 mg/kg i.a. epinephrine and cardiopulmonary bypass (resuscitation time=0 minutes). Two minutes later, external countershocks were started and repeated until defibrillation and restoration of a spontaneous heartbeat. All dogs were weaned from cardiopulmonary bypass before 5 minutes. Intermittent positive-pressure ventilation and control of physiological variables (above) were continued to 4 hours.
In group II dogs, 1.5 mg/kg U74006F was infused into the arterial cannula of the bypass circuit at 0-5 minutes. Three additional bolus intravenous injections of U74O06F were given-one (1.5 mg/kg) at 5 minutes, one (1.5 mg/kg) at 2.5 hours, and one at 4 hours of reperfusion. The latter was 0 mg/kg in one dog (total dose 4.5 mg/kg), 3 mg/kg in three dogs (total dose 7.5 mg/kg), and 10 mg/kg in one dog (total dose 14.5 mg/kg). The CBF was determined with the novel noninvasive Xe-CT method, 13 -15 adapted to cardiac arrest experiments with dogs. 16 - 18 All CBF values were obtained from a computerized analysis of CT voxel density changes during Xe washin over 4.5 minutes and are expressed as milliliters per 100 cm 3 (or gram) brain tissue per minute. The Xe washin technique is based on the Fick principle, using the CT scanner as a densitometer. Six Xe-enhanced images were obtained, beginning 30-40 seconds after the start of Xe inhalation. Constancy of the CT slices was ascertained from the consistent position of bony landmarks. Resolution in monkeys and humans seems to be 2:5x5x5=125 mm 17 were averaged to determine global and regional CBF, respectively. We calculated local CBF as the percentage of voxels in each CT slice (percentage area) having specific CBF ranges 16 -18 : no flow, 0-5 ml/100 cm 3 /min; trickle flow, 6-10 ml/100 cm 3 /min; low flow, 11-20 ml/100 cm 3 /min; normal flow for white matter, 21-40 ml/100 cmVmin; normal flow for gray matter, 41-120 ml/100 cm 3 /min; and hyperemic flow, >120 ml/100 cm V min. We arbitrarily considered gray matter with a local CBF of <20 ml/100 cm 3 /min as having inadequate CBF. Because it interferes with Xe monitoring, N 2 O was replaced by N 2 and the analgesic effect was replaced by fentanyl given as a continuous intravenous infusion of 10 ^g/kg/hr. Halothane (0.1-0.5%) was used before cardiac arrest for baseline anesthesia and MABP control. No halothane was given during CBF measurements or after cardiac arrest. The inhaled gas delivered contained 67% O 2 , the balance being N 2 , which was switched to 33% Xe during CBF measurements. Two baseline CBF studies were performed before cardiac arrest. Additional CBF studies were performed at 10 and 30 minutes and 1,1.5, 2, 3, and 4 hours after reperfusion. Before each CBF measurement, MABP, Pac^, Pacc^, arterial pH, base excess, Hct, and T CT were measured and controlled.
The CMRO 2 was determined in three dogs of group I and four dogs of group II. Via a sterile 2-cm craniotomy, a PE50 nonocclusive catheter was inserted into the sagittal sinus with the catheter tip placed 1 cm rostral to the confluence of the sinuses. For each CMRO 2 determination, the catheter dead All data were analyzed for group differences within times and for the time x group interaction using a univariate repeated-measures analysis of variance. Scheffe's post hoc procedure was used for analyzing changes within each group over time (baseline versus postarrest). The CMRO 2 data were not statistically analyzed because of small numbers. Results are reported as mean±SD.
Results
All 10 dogs in which CBF was measured followed the life support protocol. There was no difference between groups in physiological variables before or after cardiac arrest (Table 1) . Spontaneous normotension was restored within 2-3 minutes after the start of cardiopulmonary bypass. Immediately after restoration of the heartbeat, three of five dogs in each group developed brief episodes of hypertension (to peak MABP values of 130-190 mm Hg), and the others had normotensive reperfusion. Mild hemodilution caused by cardiopulmonary bypass was transient; near-baseline Hct was restored by 2-4 hours in both groups. Postarrest fentanyl and trimethaphan requirements were brief, minimal, and similar in both groups. For MABP control, dogs in group I required minimal norepinephrine at resuscitation time 0-15 minutes, while group II dogs required no norepinephrine.
In each dog, the two baseline global CBF measurements were similar (approximately 50 ml/100 cm 3 / min); there was a small standard deviation within each group and no significant difference between groups (Table 2, Figure 1 ). The first postarrest CBF measurement showed diffuse hyperemia in both groups, with essentially no voxels with no or trickle flow and fewer voxels with low flow than at baseline (i.e., there was no evidence of a protracted no-reflow phenomenon). At 30 minutes, global CBF had returned to baseline values in both groups and the percentage of voxels with a local CBF of <20 ml/100 cn r Vmin had increased above that at baseline. During the delayed protracted hypoperfusion phase at 1-4 hours postarrest, mean global CBF was 55% of baseline in group I and 53% of baseline in group II (Table 2) . At 1-4 hours, the percentage of voxels with a local CBF of <20 ml/100 cnrVmin was about 40% in both groups, significantly higher than the baseline value of about 7% in both groups (/?<0.01). There was no difference between groups (Table 2) .
Regional CBF values ( Figure 1 ) followed global CBF values (Table 2) . No region showed a significant difference between groups. The initial transient hyperemia was greatest and most prolonged in the midbrain and thalamus in both groups. During 1-4 hours postarrest, regional CBF values were about 50% of baseline values in both groups. All regional CBF values (except for the white matter) were >20 ml/100 cnrVmin in both groups.
The CaO 2 and CssO 2 values (Table 3) varied considerably between animals within times but followed a consistent pattern within dogs over time. (Table 3) were about 5-10 ml/dl analysis not appropriate (numbers per group too small). sagittal sinus oxygen content; CMRC4, global cerebral oxygen uptake; group I, control dogs (n=3); before arrest, decreased (as expected) to very low values immediately after arrest during transient hyperemia, and increased to above baseline values at 1-4 hours in all dogs, with no difference between groups. The cerebral O 2 utilization coefficient (Table  3) , 0.18-0.57 at baseline, was very low during hyperemia and about doubled (worsened) in all dogs between 1 and 4 hours postarrest. Cerebral arterial O 2 transport (Table 3) varied before cardiac arrest, increased less than expected during hyperemia (because of hemodilution), and decreased to about 50% of baseline values at 1-4 hours postarrest because CBF was about 50% of baseline at that time (Table  2) . Global (slice) CMRO 2 (Table 3 ) ranged between 2.7 and 4.5 ml/100 cm 3 /min at baseline, was 0.1-0.9 ml during hyperemia (electroencephalographic and metabolic silence), and recovered gradually toward baseline values at approximately 2-4 hours in all dogs (mismatched with low CBF). There was no difference between groups. Discussion U74006F exerts favorable cardiovascular effects. The two dogs without cardiac arrest showed that even a massive overdose (10 times the therapeutic dose) is well tolerated. In the monitored dog without cardiac arrest, 30 mg/kg i.v. U74006F almost doubled cardiac output without causing hypertension. After cardiac arrest, MABP was controlled and cardiac output was not monitored, but the U74006F-treated group required no norepinephrine while the control group did. Postarrest arrhythmias were transient and similar in the two groups. The model to 4 hours postarrest was appropriate. The same model, when life support was prolonged to 96 hours, resulted consistently in the same outcome -survival with severe brain damage 21 -22 -and mild hypothermia before 19 or after 22 arrest improved cerebral outcome. Postarrest patterns of global, regional, and local CBF and CMRO 2 were the same in both groups. CBF followed the known hyperemia-hypoperfusion sequence. 12 We used the stable Xe-CT method for CBF measurements because it is noninvasive and provides data for small regions, even regions deep within brain tissue. Verification of the Xe-CT method with autoradiography and micTosphere methods in baboons has shown that regional CBF values of foci ^5x5x5 mm 3 are real. 13 - 15 The local CBF values of 1x1x5-mm 3 voxels could partly be by chance due to system noise and possible computational and physical limitations of the method with low blood flows. 17 ' 23 '
24
The negative CBF results with use of U74006F immediately after ventricular fibrillation suggest that factors other than lipid peroxidation cascades are responsible, at least in part, for the multifocal postarrest hypoperfusion. CBF values did not change when we gave 3 mg/kg i.v. U74006F in an additional dog at 4 hours postarrest. However, acidification with acetazolamide increased CBF. 18 Thus, the hypoperfusion is not due to fixed obstruction. We have shown that deferoxamine and superoxide dismutase following asphyxiation cardiac arrest in dogs can mitigate the transient hyperemia and delayed hypoperfusion. 25 Hemodilution to a Hct of 20% improved CBF 18 but did not improve outcome unless accompanied by hypertension. 21 Mild postarrest hypother-mia (34°C) did not improve CBF 26 but improved outcome. 22 The CMRO 2 data are preliminary because of the few dogs investigated. Although for global CMRO 2 determinations we used CBF for one CT slice and arteriovenous O 2 content gradients for the entire cerebrum, the relative changes of these values are valid and baseline values were similar to those reported for the entire cerebrum. Postarrest reduction of CBF to 50% of baseline might worsen outcome only if arterial O 2 delivery is reduced below a critical level in relation to O 2 need (i.e., CMRO 2 ) and in multiple foci. In both groups, at 2 and 4 hours postarrest, approximately 50% CBF (Table 2 ) and 100% CMRO 2 (Table 3) suggest mismatching, as we reported before.--This mismatching was missed in a recent study by Michenfelder and Milde, since they reported no mismatching in dogs only up to 1 hour after cerebrospinal fluid compression ischemia.
The only published outcome study of U74006F after cardiac arrest in dogs 11 does not meet our model requirements. 22 Those investigators measured U74006F plasma levels to be 20 fig/ml immediately after a 1.5 mg/kg i.v. bolus and 0.1 yu-g/ml during a continued infusion of 0.25 mg/kg/hr. We did not measure plasma U74006F levels but infused more of the drug for longer periods. The optimal dosing and timing of U74006F are not known. After temporary, complete global brain ischemia induced by cerebrospinal fluid compression, protective pretreatment with U74006F showed benefit. 29 We conducted four pilot experiments with larger doses of U74006F, given before and/or after ventricular fibrillation of 12.5 minutes' duration in our canine outcome model 22 ; by 24-96 hours postarrest, all four dogs had a best overall performance category of 3 or 4 (severe deficit or coma), as in historic controls. 22 Outcome studies should be reexamined for life support factors that have been found to influence cerebral outcome, such as slight differences in brain temperature before 1920 or after 22 the insult or differences in perfusion pressure. 21 We conclude that U74006F, even in massive overdose, is well tolerated by the healthy organism. The established delayed postcardiac arrest cerebral hypoperfusion, mismatched by CMR0 2 returning to baseline values, does not seem to be influenced by the immediate postarrest administration of U74006F. The ability of U74006F administration after cardiac arrest to improve outcome remains to be documented with dose-response studies. If it does, it might be due to mechanisms other than improved O 2 need/O 2 delivery relations.
